AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7873474 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 7873474 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose positive inotropes (including vesnarinone)
Number of subjects: 0
Study 3068159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 40
Study 3068159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29485340 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 10
Study 29485340 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS)
Number of subjects: 10
Study 28610818 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 72
Study 28610818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 72
Study 28610818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25772326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus concurrent oral vinorelbine and capecitabine
Number of subjects: 66
Study 25772326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus sequential oral vinorelbine and capecitabine
Number of subjects: 66
Study 25772326 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating endothelial progenitors (CEP) below median
Number of subjects: 66
Study 25772326 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable circulating endothelial cells (CEC) below median
Number of subjects: 66
Study 25772326 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating endothelial progenitors (CEP) above median
Number of subjects: 66
Study 25772326 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable circulating endothelial cells (CEC) above median
Number of subjects: 66
Study 23397148 — intervention group
Group type: EXPERIMENTAL
Intervention: GLM 100 mg + MTX
Number of subjects: 19
Study 23397148 — intervention group
Group type: COMPARATOR
Intervention: PBO + MTX
Number of subjects: 19
Study 23397148 — intervention group
Group type: EXPERIMENTAL
Intervention: GLM 50 mg + MTX
Number of subjects: 19
Study 23397148 — intervention group
Group type: EXPERIMENTAL
Intervention: GLM 50 mg
Number of subjects: 19
Study 23397148 — intervention group
Group type: EXPERIMENTAL
Intervention: GLM 100 mg
Number of subjects: 19
Study 23397148 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 19
Study 23397148 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO
Number of subjects: 19
Study 22005471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin (Pem/Carb)
Number of subjects: 260
Study 22005471 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/Carboplatin (Doc/Carb)
Number of subjects: 260
Study 19695154 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 171
Study 19695154 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 171
Study 16895618 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 100
Study 16895618 — intervention group
Group type: COMPARATOR
Intervention: Control (non-acupoint site)
Number of subjects: 100
Study 15488964 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ipsapirone orally
Number of subjects: 19
Study 15488964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.002 mg/kg intravenous clonidine
Number of subjects: 19
Study 15488964 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release venlafaxine (37.5 mg, b.i.d. for low-dose responders; 75 mg, b.i.d. or higher for high-dose responders)
Number of subjects: 19
Study 15488964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10878071 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine-zalcitabine-saquinavir (soft gel capsule) [d4T-ddC-SQV(SGC)]
Number of subjects: 36
Study 9145450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre and lactulose biscuits (11 biscuits containing 10 g dietary fibre, 2 g raw fibre, 8.2 g lactulose)
Number of subjects: 10
Study 9145450 — intervention group
Group type: COMPARATOR
Intervention: Control diet without biscuits
Number of subjects: 10
Study 1435880 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fetal ventral mesencephalic tissue transplantation
Number of subjects: 4
Study 1435880 — intervention group
Group type: COMPARATOR
Intervention: Control group (one-year delay in surgery)
Number of subjects: 4
Study 3547991 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic adhesive drapes
Number of subjects: 123
Study 3547991 — intervention group
Group type: COMPARATOR
Intervention: No drape (Control)
Number of subjects: 123
Study 29687268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple contests (3 consecutive contests)
Number of subjects: 1217
Study 29687268 — intervention group
Group type: COMPARATOR
Intervention: Single contest (1 consecutive contest)
Number of subjects: 1217
Study 27196764 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (first-line treatment)
Number of subjects: 525
Study 24646647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg
Number of subjects: 124
Study 24646647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 22897465 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign Prostatic Hyperplasia Impact Index (BII)
Number of subjects: 50
Study 22897465 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept elicitation (CE) and cognitive interviewing (CI) methods
Number of subjects: 50
Study 20388497 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (CHO)
Number of subjects: 33
Study 20388497 — intervention group
Group type: COMPARATOR
Intervention: Energy-free placebo solution (PLA)
Number of subjects: 33
Study 20388497 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CHO)
Number of subjects: 33
Study 20388497 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (PLA)
Number of subjects: 33
Study 18450787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 24 weeks
Number of subjects: 40
Study 18450787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15795434 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (3.4g CLA/d in triglyceride form)
Number of subjects: 134
Study 15795434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 134
Study 15795434 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation
Number of subjects: 134
Study 12714874 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE genotype D/D
Number of subjects: 132
Study 12714874 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE genotype I/I
Number of subjects: 132
Study 12714874 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE genotype I/D
Number of subjects: 132
Study 12714874 — intervention group
Group type: COMPARATOR
Intervention: EHT patients (all genotypes)
Number of subjects: 132
Study 11188982 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B)
Number of subjects: 0
Study 11188982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8828617 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concurrent phenylalanine (Phe) levels
Number of subjects: 118
Study 8828617 — intervention group
Group type: COMPARATOR
Intervention: High concurrent phenylalanine (Phe) levels
Number of subjects: 118
Study 8828617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering concurrent phenylalanine (Phe) levels over a period of 4-5 weeks
Number of subjects: 118
Study 1364154 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 9
Study 1364154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 9
Study 1364154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 9
Study 2996905 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily (o.d.)
Number of subjects: 10
Study 2996905 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily (b.d.)
Number of subjects: 10
Study 31882606 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MFT) delivered through a smartphone app for 4 weeks
Number of subjects: 29
Study 31882606 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 29
Study 29369184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use during the entire operation (Group 1)
Number of subjects: 59
Study 29369184 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet use only at the time of cementing (Group 2)
Number of subjects: 59
Study 29369184 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet use (Group 3)
Number of subjects: 59
Study 28002896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Hyaluronic Acid (HHA); 3 injections
Number of subjects: 48
Study 28002896 — intervention group
Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (PRP); 3 injections
Number of subjects: 48
Study 25324317 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U abobotulinumtoxinA
Number of subjects: 116
Study 25324317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 22462424 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic continuous ultrasound (US)
Number of subjects: 42
Study 22462424 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (US)
Number of subjects: 42
Study 20595643 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea beverage (4 cups/d)
Number of subjects: 35
Study 20595643 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (2 capsules and 4 cups water/d)
Number of subjects: 35
Study 20595643 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea beverage and extract groups
Number of subjects: 35
Study 20595643 — intervention group
Group type: COMPARATOR
Intervention: Control (4 cups water/d)
Number of subjects: 35
Study 17907490 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high intensity LED unit (Mini LED) in fast mode (10 seconds @ 1,100 mW/cm2)
Number of subjects: 120
Study 17907490 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high intensity LED unit (Mini LED) in soft-start mode (pulse mode: ten 1-second flashes @ 1,100 mW/cm2)
Number of subjects: 120
Study 17907490 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional LED unit (Elipar Freelight) in standard mode (40 seconds @ 400 mW/cm2)
Number of subjects: 120
Study 17907490 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional LED unit (Elipar Freelight) in exponential mode (exponential increase from 0 to 400 mW/cm2 within 12 seconds followed by 28 seconds @ 400 mW/cm2)
Number of subjects: 120
Study 17907490 — intervention group
Group type: COMPARATOR
Intervention: Conventional halogen unit (Optilux) in standard mode (Control group) (40 seconds @ 600 mW/cm2)
Number of subjects: 120
Study 16236040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 16236040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 11726592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosalpinx patients
Number of subjects: 5
Study 11726592 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 5
Study 11726592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical simulations
Number of subjects: 5
Study 9142512 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly healthy subjects (75-104 years)
Number of subjects: 576
Study 7870676 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal tetracaine (1F2)
Number of subjects: 0
Study 7870676 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaxal base tetracaine
Number of subjects: 0
Study 7870676 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal tetracaine (23C2)
Number of subjects: 0
Study 7870676 — intervention group
Group type: COMPARATOR
Intervention: PEG Ointment tetracaine
Number of subjects: 0
Study 3067252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen‐androgen preparation
Number of subjects: 0
Study 3067252 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 0
Study 3067252 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen alone
Number of subjects: 0
Study 3067252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3067252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy with retained ovaries
Number of subjects: 0
Study 2351625 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg intravenous dose of cefuroxime
Number of subjects: 0
Study 2351625 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral dose of cefuroxime axetil
Number of subjects: 0
Study 2351625 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC0-6 h after oral dosage
Number of subjects: 0
Study 2351625 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated methods of assessing bioavailability
Number of subjects: 0
Study 20343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum Aspiration (VA)
Number of subjects: 420
Study 20343 — intervention group
Group type: COMPARATOR
Intervention: D & C
Number of subjects: 420
Study 20343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both D & C and Vacuum Aspiration
Number of subjects: 420
Study 31809308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 100
Study 31809308 — intervention group
Group type: COMPARATOR
Intervention: Receptive anal intercourse (RAI)
Number of subjects: 100
Study 30790345 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3008356 (DGAT1 inhibitor)
Number of subjects: 104
Study 27307397 — intervention group
Group type: EXPERIMENTAL
Intervention: MVI (misoprostol vaginal insert)
Number of subjects: 1358
Study 27307397 — intervention group
Group type: COMPARATOR
Intervention: DVI (dinoprostone vaginal insert)
Number of subjects: 1358
Study 24911427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-weight-reduction (RWR) group
Number of subjects: 0
Study 24911427 — intervention group
Group type: COMPARATOR
Intervention: Gradual-weight-reduction (GWR) group
Number of subjects: 0
Study 23268593 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 300 mg plus 100 mg dimethicone and water up to 100 ml
Number of subjects: 177
Study 23268593 — intervention group
Group type: COMPARATOR
Intervention: Dimethicone 100 mg (5 ml at 20 mg/ml) plus water up to 100 ml
Number of subjects: 177
Study 21972619 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with SSRI (observation group 1)
Number of subjects: 75
Study 21972619 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy combined with SSRI (observation group 2)
Number of subjects: 75
Study 21972619 — intervention group
Group type: COMPARATOR
Intervention: SSRI (control group)
Number of subjects: 75
Study 19858123 — intervention group
Group type: EXPERIMENTAL
Intervention: Three reminder letters mailed to GPs after dissemination of a Dementia Guideline
Number of subjects: 320
Study 19858123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder letters)
Number of subjects: 320
Study 16507185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 20 mg and ropivacaine 5 mg (Group LR)
Number of subjects: 56
Study 16507185 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine 10 mg (Group R)
Number of subjects: 56
Study 16507185 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LR
Number of subjects: 56
Study 16507185 — intervention group
Group type: COMPARATOR
Intervention: Group R
Number of subjects: 56
Study 15573335 — intervention group
Group type: EXPERIMENTAL
Intervention: Soapsuds enema
Number of subjects: 24
Study 15573335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water enema
Number of subjects: 24
Study 15573335 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte solution (PEG-ES)
Number of subjects: 24
Study 11354556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfur baths (balneotherapy) for 10 days at the Dead Sea spa
Number of subjects: 48
Study 11354556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 9216606 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic booklet group
Number of subjects: 140
Study 9216606 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 9216606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 8128430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (P), 1 mg/kg for 3 weeks, followed by either continued P for an additional 6 weeks, tapering P and beginning cyclophosphamide (C), 2 mg/kg, or continuing P and adding C.
Number of subjects: 31
Study 8128430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C), 2 mg/kg.
Number of subjects: 31
Study 8128430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Prednisone (P) and Cyclophosphamide (C).
Number of subjects: 31
Study 8128430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (P) and Cyclophosphamide (C).
Number of subjects: 31
Study 2887191 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 9
Study 2887191 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 9
Study 2887191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29641596 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifying the amount consumed of foods (type-1)
Number of subjects: 115
Study 29641596 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing food items by items from the same group or eaten at the same time (type-3)
Number of subjects: 115
Study 29641596 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing food items within the same subgroup (type-2)
Number of subjects: 115
Study 27552517 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-12286 0.5% or 0.7% topical solution, administered once daily for 24 weeks.
Number of subjects: 10
Study 27552517 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-12286 discontinued after week 24.
Number of subjects: 10
Study 26633931 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (n=26)
Number of subjects: 78
Study 26633931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (n=26)
Number of subjects: 78
Study 26633931 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% normal saline, n=26)
Number of subjects: 78
Study 24324743 — intervention group
Group type: EXPERIMENTAL
Intervention: Declarative word‐pair task
Number of subjects: 24
Study 24324743 — intervention group
Group type: COMPARATOR
Intervention: Non‐learning control task
Number of subjects: 24
Study 20514817 — intervention group
Group type: EXPERIMENTAL
Intervention: Law and justice curricula
Number of subjects: 123
Study 20514817 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction curricula
Number of subjects: 123
Study 20514817 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 123
Study 20514817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (both curricula)
Number of subjects: 123
Study 18925316 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 4 weeks
Number of subjects: 47
Study 18925316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16931936 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 (25, 50, 100, or 150 mg once-daily for 7 days)
Number of subjects: 47
Study 16931936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16931936 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278
Number of subjects: 47
Study 12745697 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative standard with performance feedback
Number of subjects: 0
Study 12745697 — intervention group
Group type: COMPARATOR
Intervention: Assigned standard with performance feedback
Number of subjects: 0
Study 12745697 — intervention group
Group type: COMPARATOR
Intervention: Monetary incentive with assigned or participative standard with feedback
Number of subjects: 0
Study 11768837 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg every 6 hours for a total of 7 doses
Number of subjects: 14
Study 11768837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg every 6 hours for a total of 7 doses
Number of subjects: 14
Study 9832953 — intervention group
Group type: COMPARATOR
Intervention: Intranasal heroin (placebo, 12.5, 25, 50, 100 mg)
Number of subjects: 5
Study 9832953 — intervention group
Group type: COMPARATOR
Intervention: Intranasal heroin (100 mg)
Number of subjects: 5
Study 9832953 — intervention group
Group type: COMPARATOR
Intervention: Intranasal heroin (various doses)
Number of subjects: 5
Study 9832953 — intervention group
Group type: COMPARATOR
Intervention: Intranasal heroin
Number of subjects: 5
Study 7971646 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (prednisone and azathioprine for 3 months)
Number of subjects: 38
Study 7971646 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38
Study 3584203 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation in a cast which restricted extension
Number of subjects: 187
Study 3584203 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 187
Study 31707770 — intervention group
Group type: EXPERIMENTAL
Intervention: wire-in (IFWE inserted and remained within the muscle during testing)
Number of subjects: 40
Study 31707770 — intervention group
Group type: EXPERIMENTAL
Intervention: wire-out (IFWE inserted and immediately removed)
Number of subjects: 40
Study 31707770 — intervention group
Group type: COMPARATOR
Intervention: baseline condition (without IFWE insertion)
Number of subjects: 40
Study 30455177 — intervention group
Group type: EXPERIMENTAL
Intervention: Default option nudge (high-value options presented as default)
Number of subjects: 120
Study 30455177 — intervention group
Group type: COMPARATOR
Intervention: Conventional menu display (no nudges)
Number of subjects: 120